Replies to post #99054 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

The studies presented were partly funded by Anavex. Could they be material needed by international partners to get them to go forward with international trials?

And yes, the recent "S1 dual role" paper was for researchers, and furthermore was not focused on our compounds. Would have been great if it showed that our compounds were strong agonists. Medicine is tricky. 2-73's relative efficacy (relative, for example, to donepezil) is not supported by this paper. However nor is it disproven. There are dosing factors, bioavailability, selectivity, etc etc. It is in human clinical trials where the rubber meets the road. A drug is ultimately measured, just like any scientific theory or mechanical tool or philosophical proposition, by its usefulness.